Overview

• The HYPO-RT-PC trial demonstrates that a 2.5-week radiotherapy regimen is as effective and safe as the traditional eight-week schedule for localized prostate cancer over a 10-year follow-up.
• Key outcomes include comparable failure-free survival (72% vs. 65%), overall survival (81% vs. 79%), and prostate cancer-specific mortality (4% in both groups).
• Long-term side effects, including urinary and bowel symptoms, were similar between the two treatment groups and remained predominantly mild to moderate.
• The shorter schedule reduces patient disruption, minimizes travel and treatment burdens, and alleviates healthcare system pressures by optimizing radiotherapy resources.
• Presented at ESTRO 2025 and published in Radiotherapy and Oncology, the findings validate precision-driven, ultra-hypofractionated approaches as a viable standard of care.